Nippon India Pharma Fund
Portfolio as on Aug 2026 · 36 equity positions
The portfolio at a glance
Nippon India Pharma Fund is a Sectoral / Thematic scheme from Nippon India MF. Its Aug 2026 portfolio holds 36 stocks, and its average assets under management are ₹8,513 Cr.
Its largest position is Sun Pharmaceutical Industries at 12.37% of the portfolio, and the ten largest together make up 56.78%.
By sector, Pharmaceuticals & Biotechnology is the largest at 75.50% of the equity portfolio, followed by Healthcare Services (21.49%) and Retailing (2.57%).
Hold other funds too? The fund overlap tool shows how many of these stocks they share. A scheme's official riskometer is in its factsheet on the fund house's website.
NAV history
₹173 per unit +1.7% vs Oct '25
Last 365 days · daily NAV from AMFI · Nippon India Pharma Fund
Performance & risk
Based on ~11 months of weekly NAV history from AMFI. Volatility is the annualized standard deviation of NAV returns. Sharpe ratio and alpha assume a 6.5% risk-free rate. Beta measures how much the fund moves with its benchmark (1.0 = in step); alpha is the return above what that beta would predict. Measured against the NAV of Kotak Nifty 50 Index Fund, standing in for the NIFTY 50 itself. A tracker's NAV is the index minus its running costs, so this compares funds against an investable benchmark rather than a costless one. Past performance does not guarantee future returns — not investment advice.
Sector allocation
- Pharmaceuticals & Biotechnology76%
- Healthcare Services21%
- Retailing3%
- Healthcare Equipment & Supplies0%
Top holdings
Top 10 holdings make up 56.8% of the portfolio · top 5 = 37.0%.
Nippon India Pharma Fund — FAQ
- What are the top holdings of Nippon India Pharma Fund?
- Nippon India Pharma Fund holds 36 equity positions; the largest is Sun Pharmaceutical Industries Ltd at 12.37% of the portfolio, as on Aug 2026. Information only, not investment advice.
- How concentrated is Nippon India Pharma Fund?
- Its single largest equity position is Sun Pharmaceutical Industries Ltd, at 12.37% of the fund's disclosed portfolio.
- As of when is this Nippon India Pharma Fund portfolio?
- Portfolio as on Aug 2026, taken from Nippon India Mutual Fund's public monthly portfolio disclosure.
- What is the NAV of Nippon India Pharma Fund?
- The latest NAV (Net Asset Value) of Nippon India Pharma Fund is ₹176.18 per unit, as on Aug 2026, sourced from AMFI's public scheme data. NAV changes daily with market movements. Information only, not investment advice.
- What is the AUM of Nippon India Pharma Fund?
- Nippon India Pharma Fund has a Monthly Average AUM (Assets Under Management) of ₹8,513 Cr, as per AMFI's latest published data. AUM reflects the total market value of all assets managed across all plans of this scheme. Information only, not investment advice.
- Who manages Nippon India Pharma Fund?
- Nippon India Pharma Fund is managed by Sailesh Raj Bhan; Kinjal Desai; Amber Singhania, as per AMFI's public disclosure. Fund manager details sourced from Kuvera/AMFI data. Information only, not investment advice.
- What is the expense ratio of Nippon India Pharma Fund?
- Nippon India Pharma Fund has a Total Expense Ratio (TER) of 1.00% p.a., as disclosed to AMFI. The TER is the annual cost of running the fund, deducted daily from the NAV. A lower TER means more of the fund's return flows to investors. Information only, not investment advice.
- What is the 1-year NAV return of Nippon India Pharma Fund?
- Nippon India Pharma Fund's NAV moved from ₹170.13 (Oct 2025) to ₹173.01 (Sep 2026), a change of 1.7% over approximately one year. NAV data sourced from AMFI. Past performance is not indicative of future returns. Information only, not investment advice.
- What is the Sharpe ratio of Nippon India Pharma Fund?
- Based on roughly 11 months of NAV history, Nippon India Pharma Fund has an annualized return of about 1.9% with 765.8% annualized volatility, giving a Sharpe ratio of -0.01 (assuming a 6.5% risk-free rate). A higher Sharpe ratio means more return per unit of risk taken. Past performance is not indicative of future returns.
- What are the beta and alpha of Nippon India Pharma Fund?
- Nippon India Pharma Fund has a beta of 0.34 and an annualized alpha of +0.2%. Beta measures how much the fund moves with its benchmark — 1.0 means it moves in step, above 1.0 amplifies it. Alpha is the return above what that beta would predict. Measured against the NAV of Kotak Nifty 50 Index Fund, standing in for the NIFTY 50 itself. A tracker's NAV is the index minus its running costs, so this compares funds against an investable benchmark rather than a costless one. Alpha assumes a 6.5% risk-free rate. The benchmark explains 13% of this fund's movement, which is low — the beta is correctly computed but says little about a fund this different from the index. Past performance is not indicative of future returns. Information only, not investment advice.
Similar funds
- ICICI Prudential Technology FundICICI Pru MF
- ICICI Prudential India Opportunities FundICICI Pru MF
- ICICI Prudential Banking & Financial Services FundICICI Pru MF
- HDFC Defence FundHDFC MF
- SBI Banking And Financial Services FundSBI MF
Equity holdings only, ISIN-verified, from Nippon India Mutual Fund's public monthly portfolio disclosure (Aug 2026). Not investment advice.
Weight = the position as a % of this fund's portfolio. Values in ₹: L = Lakh (1,00,000), Cr = Crore (1,00,00,000).